VITAMIN D ☀️.
Download this app on your mobile: dminder
"Wherever you go in the world, dminder tracks the sun and tells you when you can get Vitamin D. The stopwatch interface lets you set your session target by either amount of D to get or time. Then it will count up or down to your target, applying all the factors that determine how much D you can get: skin tone, age, weight, amount of skin exposed. All your doses of D, from the sun or supplements, are used to continuously estimate your current level. Developed with world authority on Vitamin D, Dr. Michael Holick."
http://dminder.ontometrics.com/
Download this app on your mobile: dminder
"Wherever you go in the world, dminder tracks the sun and tells you when you can get Vitamin D. The stopwatch interface lets you set your session target by either amount of D to get or time. Then it will count up or down to your target, applying all the factors that determine how much D you can get: skin tone, age, weight, amount of skin exposed. All your doses of D, from the sun or supplements, are used to continuously estimate your current level. Developed with world authority on Vitamin D, Dr. Michael Holick."
http://dminder.ontometrics.com/
I now listened to this pathologist, Dr Ryan Cole, who explains very clearly points 2 (vitamin D) and 3 (early treatment) of the Monotti Protocol. All you need to listen to are the first 25 minutes. https://youtu.be/oA-fTaGadyc
Gut bacteria and vitamin D: What is the link?
"We were surprised to find that microbiome diversity — the variety of bacteria types in a person’s gut — was closely associated with active vitamin D but not the precursor form,” says senior author of the study Dr. Deborah Kado, director of the Osteoporosis Clinic at UC San Diego Health.
“Greater gut microbiome diversity is thought to be associated with better health in general,” she adds.
https://www.medicalnewstoday.com/articles/gut-bacteria-and-vitamin-d-what-is-the-link#Stores-of-inactive-vitamin-D
"We were surprised to find that microbiome diversity — the variety of bacteria types in a person’s gut — was closely associated with active vitamin D but not the precursor form,” says senior author of the study Dr. Deborah Kado, director of the Osteoporosis Clinic at UC San Diego Health.
“Greater gut microbiome diversity is thought to be associated with better health in general,” she adds.
https://www.medicalnewstoday.com/articles/gut-bacteria-and-vitamin-d-what-is-the-link#Stores-of-inactive-vitamin-D
Medical News Today
Gut bacteria and vitamin D: What is the link?
An intriguing new study finds a significant association between gut bacteria diversity and the levels of active vitamin D in the body.
"The email identified “a significant difference in % RNA integrity/truncated species” between the clinical batches and proposed commercial batches—from around 78% to 55%. The root cause was unknown and the impact of this loss of RNA integrity on safety and efficacy of the vaccine was “yet to be defined,” the email said.
One of the most important variables relevant to all mRNA vaccines that has thus far received scant attention in the clinical community. It is an issue relevant not just to Pfizer-BioNTech’s vaccine but also to those produced by Moderna, CureVac, and others ,4 as well as a “second generation” mRNA vaccine being pursued by Imperial College London.5
RNA instability is one of the biggest hurdles for researchers developing nucleic acid based vaccines. It is the primary reason for the technology’s stringent cold chain requirements and has been addressed by encapsulating the mRNA in lipid nanoparticles (box).
“The complete, intact mRNA molecule is essential to its potency as a vaccine,” professor of biopharmaceutics Daan J.A. Crommelin and colleagues wrote in a review article in The Journal of Pharmaceutical Sciences late last year. “Even a minor degradation reaction, anywhere along a mRNA strand, can severely slow or stop proper translation performance of that strand and thus result in the incomplete expression of the target antigen.”
The Medicines and Healthcare products Regulatory Agency, the UK’s medicines regulator, acknowledged the lack of a specified percentage RNA integrity, but declined to provide further detail. “The specification limit acceptance criteria are commercially confidential,” the agency said in an email.
https://www.bmj.com/content/372/bmj.n627
One of the most important variables relevant to all mRNA vaccines that has thus far received scant attention in the clinical community. It is an issue relevant not just to Pfizer-BioNTech’s vaccine but also to those produced by Moderna, CureVac, and others ,4 as well as a “second generation” mRNA vaccine being pursued by Imperial College London.5
RNA instability is one of the biggest hurdles for researchers developing nucleic acid based vaccines. It is the primary reason for the technology’s stringent cold chain requirements and has been addressed by encapsulating the mRNA in lipid nanoparticles (box).
“The complete, intact mRNA molecule is essential to its potency as a vaccine,” professor of biopharmaceutics Daan J.A. Crommelin and colleagues wrote in a review article in The Journal of Pharmaceutical Sciences late last year. “Even a minor degradation reaction, anywhere along a mRNA strand, can severely slow or stop proper translation performance of that strand and thus result in the incomplete expression of the target antigen.”
The Medicines and Healthcare products Regulatory Agency, the UK’s medicines regulator, acknowledged the lack of a specified percentage RNA integrity, but declined to provide further detail. “The specification limit acceptance criteria are commercially confidential,” the agency said in an email.
https://www.bmj.com/content/372/bmj.n627
The BMJ
The EMA covid-19 data leak, and what it tells us about mRNA instability
Leaked documents show that some early commercial batches of Pfizer-BioNTech’s covid-19 vaccine had lower than expected levels of intact mRNA, prompting wider questions about how to assess this novel vaccine platform, writes Serena Tinari
As it conducted…
As it conducted…
Lipid nanoparticles—where do they go and what do they do?
Over the years, researchers attempted to resolve intrinsic instability by encapsulating mRNA in nanocarriers made of polymers, lipids, or inorganic materials. Lipid nanoparticles (LNPs) were chosen by Moderna, Pfizer-BioNTech, CureVac, and Imperial College London for their covid-19 vaccines.
JW Ulm, a gene therapy specialist who has published on tissue targeting of therapeutic vectors,13 raised concerns about the biodistribution of LNPs: “At present, relatively little has been reported on the tissue localisation of the LNPs used to encase the SARS-CoV-2 spike protein-encoding messenger RNA, and it is vital to have more specific information on precisely where the liposomal nanoparticles are going after injection.”
Pharmacokinetic studies, with independent laboratory confirmation, are essential to ascertain potential cytotoxicity and macroscopic toxicity, especially given the likelihood of booster injections over months or years, since the tissue trafficking patterns of the mRNA vaccine payload will determine which cells and tissues are killed by cytotoxic T-cells in each round.”
Regulators and manufacturers contacted by The BMJ for this article did not wish to address any of the questions raised by Ulm’s rapid response.
https://www.bmj.com/content/372/bmj.n627
Over the years, researchers attempted to resolve intrinsic instability by encapsulating mRNA in nanocarriers made of polymers, lipids, or inorganic materials. Lipid nanoparticles (LNPs) were chosen by Moderna, Pfizer-BioNTech, CureVac, and Imperial College London for their covid-19 vaccines.
JW Ulm, a gene therapy specialist who has published on tissue targeting of therapeutic vectors,13 raised concerns about the biodistribution of LNPs: “At present, relatively little has been reported on the tissue localisation of the LNPs used to encase the SARS-CoV-2 spike protein-encoding messenger RNA, and it is vital to have more specific information on precisely where the liposomal nanoparticles are going after injection.”
Pharmacokinetic studies, with independent laboratory confirmation, are essential to ascertain potential cytotoxicity and macroscopic toxicity, especially given the likelihood of booster injections over months or years, since the tissue trafficking patterns of the mRNA vaccine payload will determine which cells and tissues are killed by cytotoxic T-cells in each round.”
Regulators and manufacturers contacted by The BMJ for this article did not wish to address any of the questions raised by Ulm’s rapid response.
https://www.bmj.com/content/372/bmj.n627
The BMJ
The EMA covid-19 data leak, and what it tells us about mRNA instability
Leaked documents show that some early commercial batches of Pfizer-BioNTech’s covid-19 vaccine had lower than expected levels of intact mRNA, prompting wider questions about how to assess this novel vaccine platform, writes Serena Tinari
As it conducted…
As it conducted…
Face_masks_discrimination_template_letter.pdf
85.1 KB
UK: Face mask discrimination template letter.
People exempt from wearing a face covering are entitled to go about their business on the same basis as everyone else, but on just one proviso, the words "I'm exempt" must be clearly stated if challenged This is unsatisfactory for some, but the Guidance does allow service providers to check if someone wearing a mask is exempt or simply forgotten to wear a face covering. But that is as far as any service provider can legitimately go.
Again HMG states, "...we make it clear that some people may have a ‘reasonable excuse’ for not wearing face coverings, and that people do not need to prove they are exempt and should not be challenged about this. We are also clear that people should remove their face coverings to aid communication where asked, and that those accompanying or assisting people for whom a face covering will inhibit communication are not required to wear face coverings".
Face_masks_discrimination_template_letter.pdf
People exempt from wearing a face covering are entitled to go about their business on the same basis as everyone else, but on just one proviso, the words "I'm exempt" must be clearly stated if challenged This is unsatisfactory for some, but the Guidance does allow service providers to check if someone wearing a mask is exempt or simply forgotten to wear a face covering. But that is as far as any service provider can legitimately go.
Again HMG states, "...we make it clear that some people may have a ‘reasonable excuse’ for not wearing face coverings, and that people do not need to prove they are exempt and should not be challenged about this. We are also clear that people should remove their face coverings to aid communication where asked, and that those accompanying or assisting people for whom a face covering will inhibit communication are not required to wear face coverings".
Face_masks_discrimination_template_letter.pdf
Forwarded from Eshani King
Moderna's own 2012 research shows LNPs end up in your brain and in fact everywhere. Potential in brain to cause autoimmune reactions, inflammation and cause protein mis-folding (dementia/Alzheimer's risk?). Potential to impact gametes in reproductive organs.
https://thehighwire.com/videos/neuroscientists-concerns-about-covid-vaccines/
https://thehighwire.com/videos/neuroscientists-concerns-about-covid-vaccines/
The HighWire
NEUROSCIENTIST’S CONCERNS ABOUT COVID VACCINES
NEUROSCIENTIST’S CONCERNS ABOUT COVID VACCINES Neuroscientist Chris Shaw PhD shares his concerns about the mRNA #Covid19 vaccines and explains Moderna’s own data demonstrating mRNA can cross the blood-brain barrier. #ChrisShaw #DoctorsSpeakUp #Neuroscience…
"Denmark, Norway, Iceland, Austria, Estonia, Lithuania, Luxembourg, Italy, and Latvia—have suspended use of AstraZeneca’s vaccine.
On 10 March the EMA said that Austria had suspended the use of a batch of AstraZeneca vaccines after one person had multiple thrombosis diagnosed and died 10 days after vaccination. Another person was admitted to hospital with pulmonary embolism after being vaccinated and is now recovering. The EMA said that two other reports of thromboembolic event cases had also been received..
https://www.bmj.com/content/372/bmj.n699
On 10 March the EMA said that Austria had suspended the use of a batch of AstraZeneca vaccines after one person had multiple thrombosis diagnosed and died 10 days after vaccination. Another person was admitted to hospital with pulmonary embolism after being vaccinated and is now recovering. The EMA said that two other reports of thromboembolic event cases had also been received..
https://www.bmj.com/content/372/bmj.n699
The BMJ
Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
Denmark has temporarily suspended use of the Oxford-AstraZeneca covid-19 vaccine as a precautionary move after reports of blood clots and one death. However, the European Medicines Agency (EMA) and the UK’s regulatory body have said that there is no indication…
Forwarded from Fifi 4 Freedom_A Stand in the Park UK
Please feel free to print these off to promote your Stands! 🙌
Forwarded from Fifi 4 Freedom_A Stand in the Park UK
Please feel free to print these off to promote your Stands! 🙌
Forwarded from Mike Yeadon
It’s evident to me that the most likely reason for the serious adverse events is expression of spike protein which has independently been shown to trigger cell clumping over a decade ago.
Now add variable expression in different tissues plus widely varying sensitivity & that’s all that’s required to get some fatal SAEs.
If correct, all the EUA vaccines would be in the frame, with a potentially lesser concern about the Pfizer one as it’s only a portion of spike.
Now add variable expression in different tissues plus widely varying sensitivity & that’s all that’s required to get some fatal SAEs.
If correct, all the EUA vaccines would be in the frame, with a potentially lesser concern about the Pfizer one as it’s only a portion of spike.
"The SARS-CoV-2 virus is more complicated than just a spike protein. There are, in fact, four different proteins that form the overall structure of the virus particle: spike, envelope (E), membrane (M) and nucleocapsid (N). In a natural infection, our immune system recognises all of these proteins to varying degrees. So how important are immune responses to these different proteins, and does it matter that the first vaccines will not replicate these?
Following SARS-CoV-2 infection, researchers have discovered that we actually make the most antibodies to the N protein – not the spike protein. This is the same for many different viruses that also have N proteins. But how N protein antibodies protect us from infection has been a long-standing mystery. This is because N protein is only found inside the virus particle, wrapped around the RNA. Therefore, N protein antibodies cannot block virus entry, will not be measured in neutralisation assays that test for this in the lab, and so have largely been overlooked."
Following SARS-CoV-2 infection, researchers have discovered that we actually make the most antibodies to the N protein – not the spike protein. This is the same for many different viruses that also have N proteins. But how N protein antibodies protect us from infection has been a long-standing mystery. This is because N protein is only found inside the virus particle, wrapped around the RNA. Therefore, N protein antibodies cannot block virus entry, will not be measured in neutralisation assays that test for this in the lab, and so have largely been overlooked."
"Our latest work from the MRC Laboratory of Molecular Biology in Cambridge has revealed a new mechanism for how N protein antibodies can protect against viral disease. We have studied another virus containing an N protein called lymphocytic choriomeningitis virus and shown a surprising role for an unusual antibody receptor called TRIM21.
Whereas antibodies are typically thought to only work outside of cells, TRIM21 is only found inside cells. We have shown that N protein antibodies that get inside cells are recognised by TRIM21, which then shreds the associated N protein. Tiny fragments of N protein are then displayed on the surface of infected cells. T cells recognise these fragments, identify cells as infected, then kill the cell and consequently any virus."
Whereas antibodies are typically thought to only work outside of cells, TRIM21 is only found inside cells. We have shown that N protein antibodies that get inside cells are recognised by TRIM21, which then shreds the associated N protein. Tiny fragments of N protein are then displayed on the surface of infected cells. T cells recognise these fragments, identify cells as infected, then kill the cell and consequently any virus."
"N protein is very similar between different coronaviruses – much more so than the spike protein. This means it’s possible that a protective immune response against SARS-CoV-2 N protein could also offer some protection against other related coronaviruses, such as Mers.
Another potential benefit that may arise from including N protein in SARS-CoV-2 vaccines is due to the low mutation rates seen in the N protein sequence. Some changes to the sequence of SARS-CoV-2 have been reported over the course of this pandemic, with the most significant changes occurring in the spike protein. There is some concern that if the spike sequence alters too much, then new vaccines will be required. This could be similar to the current need for annual updating of influenza vaccines. However, as the N protein sequence is much more stable than the spike, vaccines that include a component targeting the N protein are likely to be effective for longer."
https://theconversation.com/covid-vaccines-focus-on-the-spike-protein-but-heres-another-target-150315
Another potential benefit that may arise from including N protein in SARS-CoV-2 vaccines is due to the low mutation rates seen in the N protein sequence. Some changes to the sequence of SARS-CoV-2 have been reported over the course of this pandemic, with the most significant changes occurring in the spike protein. There is some concern that if the spike sequence alters too much, then new vaccines will be required. This could be similar to the current need for annual updating of influenza vaccines. However, as the N protein sequence is much more stable than the spike, vaccines that include a component targeting the N protein are likely to be effective for longer."
https://theconversation.com/covid-vaccines-focus-on-the-spike-protein-but-heres-another-target-150315
The Conversation
COVID vaccines focus on the spike protein – but here’s another target
New research shows why the N protein might be a good target.
"I investigate Sage’s subcommittees: SPI-M (Scientific Pandemic Influenza Group on Modelling) and SPI-B (Scientific Pandemic Insights Group on Behaviours), which play a vital role in how it functions. There is much overlap between the bodies with some members sitting in on all three, such as Patrick Vallance (Government Chief Scientific Adviser) and Chris Whitty (Chief Medical Officer), and was also the case with the now infamous Professor Neil Ferguson of Imperial College London.
At the heart of Sage is SPI-M. It’s been driving government policy ever since the ‘war’ on Covid-19 began. Only very few media outlets, such as TCW and the Daily Mail, have questioned the ‘dodgy data’ derived from its computerised type of modelling. Anyone who suggests it is not perfect is often branded a ‘Covid denier’.
The man who ran the show at SPI-M at the start of the pandemic was Neil Ferguson. He is also acting director of Vaccine Impact Modelling Consortium (VIMC) based at Imperial College, which is funded by GAVI-The Vaccine Alliance, in turn funded by the Bill and Melinda Gates Foundation as TCW reported here."
https://www.conservativewoman.co.uk/sages-covert-coup-part-two-project-fear/
At the heart of Sage is SPI-M. It’s been driving government policy ever since the ‘war’ on Covid-19 began. Only very few media outlets, such as TCW and the Daily Mail, have questioned the ‘dodgy data’ derived from its computerised type of modelling. Anyone who suggests it is not perfect is often branded a ‘Covid denier’.
The man who ran the show at SPI-M at the start of the pandemic was Neil Ferguson. He is also acting director of Vaccine Impact Modelling Consortium (VIMC) based at Imperial College, which is funded by GAVI-The Vaccine Alliance, in turn funded by the Bill and Melinda Gates Foundation as TCW reported here."
https://www.conservativewoman.co.uk/sages-covert-coup-part-two-project-fear/
The Conservative Woman
Sage’s covert coup Part Two – Project Fear - The Conservative Woman